Just the FACTs 2022 Volume 6
Letter from the President
With the closing of 2022, I, and the FACT Board of Directors, reflected on accomplishments achieved this year and the impact those accomplishments will have in the coming year. FACT is pleased with the tremendous progress we have made to further advance our mission well into the future.
In 2022, following the transition to independent status, after a 25-year partnership with the University of Nebraska Medical Center, FACT welcomed many new faces to its international headquarters and developed a strategic plan for the next three years. We are excited to share our plans to strengthen our existing services and leverage our expertise to serve unmet needs. Both of these are necessary to meet the unprecedented demand for cellular therapies from cancer and beyond. This is going to be extremely critical as more cell therapies obtain licensure and is particularly topical this month when Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) receives European Commission approval “as the first ever therapy for adults and children with EBV+ PTLD”.
In addition, I hope you will see in this newsletter an important announcement regarding the online accreditation portal. We are eager to implement a major upgrade in February to better serve our accredited programs and volunteer inspectors.
Thank you so much for another year rising to the challenge to offer care to an ever-increasing number of people in need. FACT is so proud to participate in efforts to increase the quality of and access to cellular therapy in terms of geography, resources, and indications. None of this would be possible without you.
Sending you all heartfelt thanks and wishing you a very happy time over the holidays and looking forward to exciting times ahead in 2023!
Catherine M. Bollard, MD